About HLB
HLB is a publicly listed company based in Ulsan (South Korea) founded in 1985. Marine composite materials are manufactured for industry applications. The company has 168 employees. HLB has completed 2 acquisitions, including Anygen and GtreeBNT. Its chief executive, as recorded, is Jin Yang Gon. Its website hlbkorea.com draws about 15 thousand monthly visits. HLB offers products and services including Rivoceranib and Other Therapies. Its legal entity is HLB CO.,LTD.
Company details
HLB, established in 1985 and currently in Public stage, focuses on manufacturer of marine composite materials. Manufacturer of marine composite materials. Adapting to market demands with innovation. It continues to evolve, meeting industry challenges with strategic approaches and commitment to quality.
- Headquarters Ulsan, South Korea
- Employees 168
- Stage Public
- Email••••••••
- Phone•••• ••••
- Website hlbkorea.com
- Social LinkedIn Facebook
- Legal Name Hlb Co., Ltd.
- Annual Revenue$58.28 M (USD)23.55as on Dec 31, 2025
- Net Profit-$152.68 M (USD)-139.73as on Dec 31, 2025
- EBITDA-$65.05 M (USD)16.44as on Dec 31, 2025
- Investors
- Employee Count168
- Investments & AcquisitionsAnygen
& 1 more
Products & Services of HLB
HLB offers a comprehensive portfolio of products and services, including Rivoceranib and Other Therapies.
Rivoceranib is positioned as a targeted therapy for various cancers, including liver and lung cancers, that is developed to meet specific medical needs
Other therapies such as CAR-T and immune therapies are offered under HLB's pharmaceutical portfolio to address a range of oncology applications
Funding Insights of HLB
- Total Rounds 1
- Investors Count 1
All 1 funding rounds of HLB with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2017 | Post-IPO | – | – |
1 investors in total: 1 institutional.
Investors in HLB
HLB has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include E&Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| eninvestment.co.kr |
Investor details for HLB
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of HLB
1 people are tracked at HLB (1 in leadership); the tracked headcount is 168.
| Name | Role | Group |
|---|---|---|
Jin Yang Gon | CEO | Leadership |
Complete people profiles for HLB
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of HLB
HLB is a publicly listed company on the KRX with ticker symbol 028300 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date27 Jul 1996
- Listed onKRX: 028300
- Listed entityHLB Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7028300002
- Share price42,000.00 KRW (-4.55% on the day) · 2026-10-14
- Market capitalisation5,849,456,787,109.00 KRW
- EPS (diluted, trailing year)-1,615.17 KRW
- Volume (last session)680,123
Financials of HLB
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 84.17B KRW | -220.50B KRW | -93.95B KRW |
| 2024 | 68.13B KRW | -91.98B KRW | -112.44B KRW |
| 2023 | 42.90B KRW | -187.55B KRW | -106.33B KRW |
| 2022 | 179.71B KRW | -78.16B KRW | -58.34B KRW |
| 2021 | 69.83B KRW | -98.13B KRW | -87.80B KRW |
Detailed financial statements for HLB
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by HLB
HLB has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Anygen and GtreeBNT.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Peptide API and drug developer for cancer & pain disorders | anygen.com | Gwangju, South Korea | 2000 | Mar 2025 | •••• | |
Therapies for brain cancer treatment are developed by GtreeBNT. | gtreebnt.com | Seongnam-si, South Korea | 2000 | Sep 2021 | •••• |
Complete acquisition details for HLB
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Web traffic of HLB
The website of HLB (hlbkorea.com) receives about 15.5K visits a month.
- Monthly visits15.5K
▲ 11.4% vs previous month
Websites whose visitors overlap most with HLB. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| hlb-ls.com | 100% | 4.1K | #4,652,140 | View details | |
delighti.co.kr | delighti.co.kr | 89% | #935,405 | – | |
fntimes.com | fntimes.com | 84% | #129,903 | – | |
dealsite.co.kr | dealsite.co.kr | 79% | #47,739 | – | |
newsdream.kr | newsdream.kr | 78% | #859,237 | – | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 17 similar websites and full traffic analytics for HLB
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 17 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hlb
Complete news archive for HLB
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about HLB
HLB was founded in 1985 and raised its 1st funding round 32 years after it was founded.
HLB is headquartered in Ulsan, South Korea.
Jin Yang Gon is the CEO of HLB, as recorded in our data.
HLB has 168 employees.
Annual revenue of HLB is $58.28M as on Dec 31, 2025.
HLB, established in 1985 and currently in Public stage, focuses on manufacturer of marine composite materials. Manufacturer of marine composite materials. Adapting to market demands with innovation. It continues to evolve, meeting industry challenges with strategic approaches and commitment to quality.
HLB offers Rivoceranib and Other Therapies.
Yes, HLB is publicly traded on KRX under the ticker symbol 028300.
HLB has 1 investor. Key investors include E&Investment.
HLB operates through Hlb Co.,Ltd.